Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
Neurocrine Biosciences reported Q1 2026 total net product sales of $811.0 million, up 44% year-over-year, driven by strong demand for INGREZZA and CRENESSITY. The company reaffirmed its full-year 2026 INGREZZA net sales guidance of $2.7 billion to $2.8 billion and announced a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, representing a total equity value of $2.9 billion.
Key figures
- Eps
- 1.91
- Revenue
- 814500000
- Drug Name
- NBI-1117570
- Guidance
- FY2026 INGREZZA Net Product Sales $2.7B - $2.8B
- Revenue Yoy
- 42%
- Deal Value Usd
- 2900000000
- Phase Of Trial
- Phase 2
- Net income
- 197900000
- Cressity sales
- 153300000
- Ingrezza sales
- 656900000
- Cash equivalents
- 2647200000
- Operating income
- 193400000
- Net product sales
- 811000000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.